Literature DB >> 25100148

D-dimer as a significant marker of deep vein thrombosis in patients with subclinical or overt Cushing's syndrome.

Hidenori Fukuoka1, Takehito Takeuchi, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Yushi Hirota, Genzo Iguchi, Yutaka Takahashi.   

Abstract

Venous thromboembolism (VTE) is frequently associated with hypercortisolemia. This retrospective single-center study aimed to clarify the significance of plasma D-dimer levels for VTE screening in patients with subclinical or overt Cushing's syndrome (soCS). A total of 72 consecutive treatment-naïve patients with soCS diagnosed at Kobe University Hospital between 2002 and 2014 were enrolled. Patients with both lower extremity ultrasound and D-dimer measurement data (n = 19) were recruited in study 1 and divided into 2 groups, a deep vein thrombosis (DVT) (-) group (n = 12) and DVT (+) group (n = 7) for a comparison of the associated factors. The age and D-dimer levels were higher in the DVT (+) group than in the DVT (-) group (p = 0.04 and 0.02, respectively). A receiver operating characteristic analysis found that D-dimer level ≥2.6 μg/mL correlated with the presence of DVT (sensitivity, 100%; specificity, 91.7%). Next, patients with D-dimer measurement data (n = 36) were recruited in study 2 and divided into 2 groups according to D-dimer level: D-dimer (-), <1 μg/mL group (n = 23) and D-dimer (+), ≥1 μg/mL group (n = 13); the groups were compared with respect to various VTE-related risk factors. A logistic regression analysis revealed that elevated cortisol level after low-dose dexamethasone suppression was a significant risk factor for D-dimer elevation (OR = 1.21, p = 0.02). In conclusion, these data demonstrate that a D-dimer level ≥2.6 μg/mL is an indicator of DVT in treatment naïve patients with soCS and suggests that relatively high autonomous cortisol secretion may be associated with thrombus formation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25100148     DOI: 10.1507/endocrj.ej14-0102

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  5 in total

1.  Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.

Authors:  Atsushi Isoda; Naru Sato; Yuri Miyazawa; Yoshinobu Matsumoto; Mina Koumoto; Masahito Ookawa; Morio Sawamura; Morio Matsumoto
Journal:  Int J Hematol       Date:  2015-07-16       Impact factor: 2.490

2.  CUSHING'S SYNDROME, A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IS A CANDIDATE FOR GUIDELINES.

Authors:  G Koraćević; M Stojanović; S Petrović; D Simić; D Sakač; M Vlajković; M Stevic; M Kocić; M Đorđević; M Koraćević
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

3.  Relationship between serum cortisol level and degree of false lumen thrombosis in patients with uncomplicated type B aortic dissection.

Authors:  Yani Wu; Yudong Sun; Xiaolong Wei; Lei Zhang; Tonglei Han; Zhiqing Zhao; Jian Zhou; Zaiping Jing
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

Review 4.  Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Authors:  Masaaki Yamamoto; Takahiro Nakao; Wataru Ogawa; Hidenori Fukuoka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

5.  Multiple Salivary Cortisol Measurements Are a Useful Tool to Optimize Metyrapone Treatment in Patients with Cushing's Syndromes Treatment: Case Presentations.

Authors:  Kenichi Yoshida; Hidenori Fukuoka; Yukiko Odake; Shinsuke Nakajima; Mariko Tachibana; Jun Ito; Yusei Hosokawa; Tomoko Yamada; Hiroshi Miura; Natsu Suematsu; Ryusaku Matsumoto; Hironori Bando; Kentaro Suda; Hitoshi Nishizawa; Genzo Iguchi; Wataru Ogawa; Yutaka Takahashi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-11       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.